Pharma Focus Asia

InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China

Tuesday, May 18, 2021

InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that China National Medical Products Administration has approved the Phase I clinical trial of InnoCare’s novel TYK2 (Tyrosine Kinase 2) inhibitor, which becomes the company’s fifth innovative drug to enter the clinical phase.

InnoCare developed oral ICP-332 with global IP rights. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway, playing an important role in the pathogenesis of inflammatory diseases. Currently no selective TYK2 inhibitor has entered the market globally.

ICP-332 is designed to be a potent and selective TYK2 inhibitor with 400 folds of selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors. ICP-332 will be used to treat autoimmune diseases such as psoriasis and atopic dermatitis.

Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare said, "We are committed to our core value of ‘Science drives innovation for the benefit of patients’. The approval of ICP-332 clinical trial enriches our drug pipeline and it is the fifth innovative drug to enter the clinical phase, further strengthening our pipeline in autoimmune diseases. We will push forward the clinical trials to benefit patients.”

Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024